Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853687 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL20903815 | 0.82 | TSHR (0.37) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL6377681 | 0.81 | ALDH1A1 (0.53) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL6378134 | 0.81 | ALDH1A1 (0.53) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL10064912 | 0.81 | LMNA (0.40) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL25454247 | 0.81 | ALDH1A1 (0.36) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL1746242 | 0.81 | ALDH1A1 (0.53) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL2871721 | 0.80 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL98282 | 0.80 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL3421776 | 0.80 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1157000-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER LAMBERT CO (US) | 2005-11-02 | — | — | EP | claimed |
| CN-1626069-A | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy | WARNER LAMBERT CO (US) | 2005-06-15 | — | — | CN | claimed |
| EP-1157000-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2001042191-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-06-14 | — | — | WO | claimed |
| WO-2020122838-A2 | A COMBINATION COMPRISING A MULTIPLE SCLEROSIS AGENT AND AT LEAST ONE ANTI-EPILEPTIC AGENT | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2020-06-18 | — | — | WO | disclosed |
| US-9739780-B2 | Metabolite biomarkers for the detection of liver cancer | PURDUE RESEARCH FOUNDATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen, Inc. (CA) | 2017-02-16 | — | — | US | disclosed |
| US-9481637-B2 | Compounds for the treatment of seizures and other central nervous systems disorders and conditions | Ketogen Inc. (CA) | 2016-11-01 | — | — | US | disclosed |
| WO-2015184542-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-10 | — | — | WO | disclosed |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | Ketogen Inc. (CA) | 2015-12-03 | — | — | US | disclosed |
| US-9187427-B2 | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2015-11-17 | — | — | US | disclosed |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | CELLIX BIO PRIVATE LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20080199887-A1 | COMPOUNDS AND METHODS FOR USE IN DETECTING GABAPENTIN | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2008-08-21 | — | — | US | disclosed |
| EP-1157000-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER LAMBERT CO (US) | 2005-11-02 | — | — | EP | disclosed |
| CN-1626069-A | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy | WARNER LAMBERT CO (US) | 2005-06-15 | — | — | CN | disclosed |
| WO-2004093780-A2 | PROCESS FOR THE PREPARATION OF GABAPENTIN FORM-II | MATRIX LABORATORIES LTD (IN) | 2004-11-04 | — | — | WO | disclosed |
| EP-1157000-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001042191-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199887-A1 | COMPOUNDS AND METHODS FOR USE IN DETECTING GABAPENTIN | GABRE, GABRG3, GABRB2 | ALDH1A1 1863/4885CYP1A2 3525/4885USP2 2497/4885 |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | ALDH1A1 3897/4885CYP1A2 1037/4885USP2 2160/4885 |
| US-20150152060-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT MIGRAINE AND NEUROLOGIC DISEASES | PSEN1, APP, PSEN2 | ALDH1A1 3498/4885CYP1A2 498/4885USP2 4679/4885 |
| US-20170044095-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | ALDH1A1 640/4885CYP1A2 370/4885USP2 3434/4885 |
| US-20150344413-A1 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS | PC, PYGB, GLS2 | ALDH1A1 640/4885CYP1A2 370/4885USP2 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.